MONTREAL, CANADA--(Marketwired - May 20, 2015) - Theratechnologies Inc. (TSX:TH) today held its annual meeting of shareholders, chaired by Dawn Svoronos, chair of the board of Theratechnologies.

During the meeting, management reviewed last year's financial and corporate highlights. It also discussed the Company's perspectives for the future.

"Last year most definitely marked a significant milestone in Theratechnologies' history. Regaining rights to EGRIFTA™ (tesamorelin for injection) in the United States is the spearhead of a most promising approach on which we have based our growth and profitability business model. During the next year, our priority will be to sustain efforts in that territory while preparing for the Canadian launch," said Luc Tanguay, President and CEO, Theratechnologies Inc.

As part of the meeting, the following people were elected as directors of the Company by a majority of the votes.


Gérald A. Lacoste 19,151,474 99.60 76,862 0.40
David Lilley 19,149,304 99.59 79,032 0.41
Paul Pommier 19,149,674 99.59 78,662 0.41
Dawn Svoronos 19,179,084 99.74 49,252 0.26
Jean-Denis Talon 19,148,974 99.59 79,362 0.41
Luc Tanguay 19,177,754 99.74 50,582 0.26

This represents the first mandate for David Lilley as board member of Theratechnologies.

"David's impressive track record in the pharmaceutical sector will certainly be most useful to our company and I take this opportunity to welcome him. His expertise is very timely as Theratechnologies enters a new phase of its existence," said Dawn Svoronos, Chair of the Board, Theratechnologies Inc.

At the meeting, KPMG was appointed as auditors of the Company.

About Theratechnologies

Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and improved quality of life.

Forward-Looking Information

This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation, which statements may contain such words as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions. This forward-looking information includes, but is not limited to, information regarding the growth and profitability of our Company and the launch of our product in Canada.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, the fact that the Company's business model will be followed and that no external events will cause modifications to the said business plan and that sales of the product in the United States will continue to grow. These risks and uncertainties include, but are not limited to, that sales of the product by the Company stagnate or decline, as a result of still unknown side-effects, the loss of reimbursement from third-party payers or an order by regulatory authorities to withdraw the product.

We refer potential investors to the "Risk Factors" section of our Annual Notice Form dated February 25, 2015 available at and The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.

Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Contact Information:

Denis Boucher